Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free FGEN Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

FibroGen (FGEN) Financials

FibroGen logo
Compare
Annual Income Statements for FibroGen

Annual Income Statements for FibroGen

This table shows FibroGen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -86 -58 - -86 -77 -189 -290 -294 -284 -48 183
Consolidated Net Income / (Loss)		 -86 -58 - -86 -77 -189 -290 -294 -284 -48 183
Net Income / (Loss) Continuing Operations		 -86 -58 - -86 -77 -189 -290 -294 -323 -153 -58
Total Pre-Tax Income 		-86 -58 - -86 -77 -189 -291 -295 -323 -153 -58
Total Operating Income		 -78 -50 - -87 -89 -192 -289 -301 -323 -150 -46
Total Gross Profit		 181 183 - 213 255 167 222 120 43 14 5.88
Total Revenue		 181 183 - 213 257 176 235 141 47 30 6.44
Operating Revenue		 181 183 - 213 257 176 235 141 47 30 6.44
Total Cost of Revenue		 0.00 0.00 - 0.00 1.15 8.87 13 20 3.96 16 0.56
Operating Cost of Revenue		 - - - 0.00 1.15 8.87 - - 3.96 16 0.56
Total Operating Expenses		 258 233 - 300 345 359 511 421 366 164 52
Selling, General & Admin Expense		 44 46 - 64 135 106 124 125 86 49 28
Research & Development Expense		 214 187 - 236 209 253 387 297 266 96 24
Restructuring Charge		 - - - - - - 0.00 0.00 13 19 0.55
Total Other Income / (Expense), net		 -7.91 -8.10 - 0.58 13 3.15 -2.15 6.16 -1.00 -2.95 -12
Interest Expense		 11 11 - 11 2.88 2.40 1.08 1.44 8.10 8.25 15
Other Income / (Expense), net		 - - - - 16 5.55 -1.08 7.60 7.59 5.30 2.94
Income Tax Expense		 0.24 -0.07 - 0.30 0.33 0.36 0.35 0.36 -0.25 -0.27 -0.09
Net Income / (Loss) Discontinued Operations		 - - - - - - - - 39 106 242
Basic Earnings per Share		 ($1.42) ($0.93) - ($1.03) ($0.89) ($2.11) ($3.14) ($3.14) ($2.92) ($11.89) $45.37
Weighted Average Basic Shares Outstanding		 60.34M 62.74M 72.99M 84.06M 86.63M 89.85M 92.35M 93.58M 97.30M 4.00M 4.04M
Diluted Earnings per Share		 ($1.42) ($0.93) - ($1.03) ($0.89) ($2.11) ($3.14) ($3.14) ($2.92) ($11.89) $45.37
Weighted Average Diluted Shares Outstanding		 60.34M 62.74M 72.99M 84.06M 86.63M 89.85M 92.35M 93.58M 97.30M 4.00M 4.04M
Weighted Average Basic & Diluted Shares Outstanding		 60.34M 62.74M 72.99M 84.06M 86.63M 89.85M 92.35M 94.18M 98.77M 100.92M 4.05M

Quarterly Income Statements for FibroGen

This table shows FibroGen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -64 -56 -33 -16 -17 18 4.64 -7.60 201 -14 -15
Consolidated Net Income / (Loss)		 -64 -56 -33 -16 -17 18 4.64 -7.60 201 -14 -15
Net Income / (Loss) Continuing Operations		 -64 -95 -49 -47 -48 -88 -17 -14 -13 -15 -15
Total Pre-Tax Income 		-64 -93 -49 -47 -48 -85 -17 -14 -13 -15 -15
Total Operating Income		 -63 -95 -49 -46 -48 -92 -15 -12 -5.41 -14 -14
Total Gross Profit		 36 -64 4.02 0.86 0.20 -103 2.49 1.26 1.13 1.00 -0.37
Total Revenue		 40 -74 25 1.00 0.12 -123 2.74 1.35 1.08 1.28 3.74
Operating Revenue		 40 -74 25 1.00 0.12 -123 2.74 1.35 1.08 1.28 3.74
Total Cost of Revenue		 4.24 -9.48 21 0.14 -0.08 -21 0.25 0.09 -0.06 0.28 4.11
Operating Cost of Revenue		 4.24 -9.48 21 0.14 -0.08 -21 0.25 0.09 -0.06 0.28 4.11
Total Operating Expenses		 99 31 53 47 48 -11 17 13 6.55 15 13
Selling, General & Admin Expense		 26 -4.55 17 15 9.36 -13 8.11 7.06 5.30 7.25 5.86
Marketing Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Research & Development Expense		 61 35 36 32 20 1.49 9.18 5.87 1.21 7.27 7.57
Restructuring Charge		 13 - 0.00 0.00 19 0.90 0.13 0.39 0.04 -0.01 0.02
Total Other Income / (Expense), net		 -0.73 1.48 0.14 -0.97 -0.60 6.73 -1.84 -1.72 -7.74 -1.10 -1.31
Interest Expense		 5.02 -2.37 2.09 1.87 2.07 -6.53 2.26 2.01 8.67 2.41 2.43
Interest & Investment Income		 0.00 -0.50 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Other Income / (Expense), net		 4.30 -0.39 2.24 0.90 1.47 0.21 0.41 0.29 0.93 1.31 1.11
Income Tax Expense		 0.08 -0.18 0.01 -0.28 0.00 -0.05 0.00 -0.09 0.00 - 0.00
Net Income / (Loss) Discontinued Operations		 - - 16 32 31 - 21 6.08 214 0.39 -0.07
Basic Earnings per Share		 ($0.65) ($0.56) ($0.33) ($3.89) ($4.25) $0.18 $1.15 ($1.88) $49.61 ($3.52) ($3.76)
Weighted Average Basic Shares Outstanding		 98.25M 97.30M 98.98M 3.99M 4.02M 100.04M 4.04M 4.04M 4.04M 4.04M 4.05M
Diluted Earnings per Share		 ($0.65) ($0.56) ($0.33) ($3.89) ($4.25) $0.18 $1.15 ($1.88) $49.61 ($3.52) ($3.76)
Weighted Average Diluted Shares Outstanding		 98.25M 97.30M 98.98M 3.99M 4.02M 100.04M 4.04M 4.04M 4.04M 4.04M 4.05M
Weighted Average Basic & Diluted Shares Outstanding		 98.34M 98.77M 99.48M 100.40M 100.77M 100.92M 101.04M 4.04M 4.05M 4.05M 4.05M

Annual Cash Flow Statements for FibroGen

This table details how cash moves in and out of FibroGen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -12 20 500 -584 37 552 -507 -16 -42 -12 -54
Net Cash From Operating Activities		 -19 7.11 -67 -76 -79 82 -82 -146 -315 -138 -4.77
Net Cash From Continuing Operating Activities		 -19 7.11 -67 -76 -79 82 -82 -146 -315 -138 -4.77
Net Income / (Loss) Continuing Operations		 -86 -58 -121 -86 -77 -189 -290 -294 -284 -48 183
Consolidated Net Income / (Loss)		 -86 -58 -121 -86 -77 -189 -290 -294 -284 -48 183
Depreciation Expense		 5.68 6.04 6.10 6.56 11 12 10 10 9.52 2.65 0.71
Amortization Expense		 3.00 2.73 1.84 -0.04 6.64 10 7.12 2.21 -4.65 -1.64 -0.04
Non-Cash Adjustments To Reconcile Net Income		 28 32 38 52 65 74 130 65 84 95 -27
Changes in Operating Assets and Liabilities, net		 31 24 8.00 -48 -84 175 60 70 -120 -186 -162
Net Cash From Investing Activities		 -5.87 6.62 70 -522 120 452 -427 89 154 126 35
Net Cash From Continuing Investing Activities		 -5.87 6.62 70 -522 120 452 -427 89 154 126 35
Purchase of Property, Plant & Equipment		 -1.98 -1.25 -8.50 -8.02 -5.76 -3.99 -5.19 -3.74 -2.52 -0.27 -0.04
Purchase of Investments		 -42 -9.04 -0.17 -577 -411 -8.19 -484 -164 -252 -8.63 -61
Sale of Property, Plant & Equipment		 0.00 0.00 0.01 0.18 0.01 0.00 0.00 0.01 0.00 1.05 0.00
Divestitures		 - - - - - - 0.00 0.00 0.66 0.00 97
Sale and/or Maturity of Investments		 38 17 79 63 537 468 87 292 407 134 0.00
Net Cash From Financing Activities		 12 6.74 496 14 -4.30 13 -0.56 47 123 -0.26 -86
Net Cash From Continuing Financing Activities		 12 6.74 496 14 -4.30 13 -0.56 47 123 -0.26 -86
Repayment of Debt		 -0.40 -0.40 -0.40 -0.41 -12 -0.40 -0.40 -0.40 -3.08 -0.04 -81
Payment of Dividends		 - - - - - - - - - 0.00 -5.35
Issuance of Common Equity		 15 9.88 35 30 21 38 13 4.18 52 0.14 0.00
Other Financing Activities, net		 -2.24 -2.74 463 -16 -13 -24 -13 43 -0.39 -0.35 -0.07
Effect of Exchange Rate Changes		 -0.04 - 0.05 - -0.01 4.70 - - - 0.75 1.08
Cash Interest Paid		 0.34 0.30 0.26 0.22 0.17 0.14 0.09 0.10 6.38 16 7.83

Quarterly Cash Flow Statements for FibroGen

This table details how cash moves in and out of FibroGen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -32 -7.23 -7.95 35 -9.71 -29 4.02 14 -1.87 -70 -11
Net Cash From Operating Activities		 -85 -18 -59 -40 -8.38 -30 2.72 13 -1.85 -18 -14
Net Cash From Continuing Operating Activities		 -85 -18 -59 -40 -8.38 -30 2.72 13 -1.85 -18 -14
Net Income / (Loss) Continuing Operations		 -64 -56 -33 -16 -17 18 4.64 -7.60 201 -14 -15
Consolidated Net Income / (Loss)		 -64 -56 -33 -16 -17 18 4.64 -7.60 201 -14 -15
Depreciation Expense		 2.63 1.87 0.81 0.77 0.73 0.34 0.32 0.21 0.18 - 0.00
Amortization Expense		 -2.09 -1.40 -1.28 -0.38 0.01 0.01 0.01 0.01 0.01 -0.07 -0.18
Non-Cash Adjustments To Reconcile Net Income		 7.80 11 7.82 6.18 13 -65 5.10 4.25 -40 3.96 2.25
Changes in Operating Assets and Liabilities, net		 -29 27 -34 -31 -5.22 16 -7.35 16 -162 -8.00 -0.76
Net Cash From Investing Activities		 54 10 51 72 0.76 1.72 -0.02 -0.01 87 -52 3.02
Net Cash From Continuing Investing Activities		 54 10 51 72 0.76 1.72 -0.02 -0.01 87 -52 3.02
Purchase of Property, Plant & Equipment		 -0.68 -0.25 -0.03 -0.01 -0.08 -0.14 -0.02 -0.01 -0.01 - 0.00
Acquisitions		 - - 0.00 - - - 0.00 - - - -0.06
Purchase of Investments		 -53 -95 -8.63 - - - 0.00 - -3.04 -58 -11
Divestitures		 - - 0.00 - - - 0.00 - 90 6.41 0.00
Sale and/or Maturity of Investments		 108 105 60 72 - 1.66 0.00 - - - 14
Net Cash From Financing Activities		 -0.02 -0.25 -0.17 0.03 -0.13 0.01 -0.09 -0.01 -86 -0.01 -0.01
Net Cash From Continuing Financing Activities		 -0.02 -0.25 -0.17 0.03 -0.13 0.01 -0.09 -0.01 -86 -0.01 -0.01
Repayment of Debt		 0.11 -0.03 -0.01 0.01 - - -0.05 - -81 -0.01 0.00
Other Financing Activities, net		 -0.13 -0.26 -0.15 -0.10 -0.13 -0.02 -0.04 -0.01 -0.01 -0.00 -0.01
Effect of Exchange Rate Changes		 - - 0.22 - - - - - - - 0.00

Annual Balance Sheets for FibroGen

This table presents FibroGen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 471 470 899 881 857 827 774 610 424 215 120
Total Current Assets		 201 267 749 690 702 755 474 493 332 197 99
Cash & Equivalents		 153 174 674 89 126 678 171 156 82 50 48
Short-Term Investments		 28 79 62 532 407 8.14 234 266 122 0.00 41
Accounts Receivable		 15 10 8.45 64 28 42 17 16 5.12 0.48 0.22
Inventories, net		 - - - 0.00 6.89 17 31 40 17 3.16 3.74
Prepaid Expenses		 3.99 2.89 4.80 4.93 133 10 20 14 40 32 6.14
Other Current Nonoperating Assets		 - - - - - - - - 66 111 0.00
Plant, Property, & Equipment, net		 129 124 129 127 43 34 28 21 4.79 0.00 0.00
Total Noncurrent Assets		 141 79 20 63 112 38 271 97 87 18 21
Long-Term Investments		 132 71 11 56 61 2.73 172 9.41 - 0.00 20
Other Noncurrent Operating Assets		 9.27 8.37 9.70 7.57 11 3.43 98 85 67 1.41 0.36
Other Noncurrent Nonoperating Assets		 - - - - - 2.07 2.07 2.07 20 17 0.00
Total Liabilities & Shareholders' Equity		 471 470 899 881 857 827 774 610 424 215 120
Total Liabilities		 274 294 351 352 322 385 545 612 586 398 115
Total Current Liabilities		 67 65 86 89 103 163 225 274 218 133 29
Accounts Payable		 6.52 6.22 5.51 9.14 6.09 25 26 31 16 5.06 3.75
Accrued Expenses		 48 51 64 66 84 118 173 220 133 62 20
Current Deferred Revenue		 13 7.99 17 14 0.49 6.55 16 13 13 27 5.31
Other Current Liabilities		 - - - 0.00 12 14 11 10 13 0.00 0.00
Other Current Nonoperating Liabilities		 - - - - - - - - 44 39 0.00
Total Noncurrent Liabilities		 207 229 265 263 219 222 319 338 368 265 86
Long-Term Debt		 - - - - - - - 0.00 72 73 0.00
Noncurrent Deferred Revenue		 90 111 142 139 99 138 187 186 158 115 0.26
Other Noncurrent Operating Liabilities		 20 21 25 27 82 58 132 152 137 77 86
Other Noncurrent Nonoperating Liabilities		 - - - - - - - - 1.50 0.36 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - - 0.00 21 21 21
Total Equity & Noncontrolling Interests		 197 175 548 528 535 441 229 -1.48 -184 -205 -17
Total Preferred & Common Equity		 178 156 528 509 516 422 209 -21 -204 -226 -30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 178 156 528 509 516 422 209 -21 -204 -226 -30
Common Stock		 587 627 1,161 1,227 1,302 1,401 1,477 1,542 1,645 1,670 1,678
Retained Earnings		 -408 -470 -631 -716 -785 -974 -1,264 -1,558 -1,842 -1,889 -1,706
Accumulated Other Comprehensive Income / (Loss)		 -1.65 -0.96 -1.80 -2.28 -0.75 -4.50 -4.16 -5.72 -6.88 -5.73 -2.18
Noncontrolling Interest		 19 19 19 19 19 19 20 20 20 20 13

Quarterly Balance Sheets for FibroGen

This table presents FibroGen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 460 366 293 264 165 178 137 110
Total Current Assets		 364 278 209 245 149 162 133 101
Cash & Equivalents		 121 106 141 131 34 23 118 37
Short-Term Investments		 130 72 0.00 0.00 0.00 0.00 0.00 50
Accounts Receivable		 32 37 6.41 29 0.15 0.14 0.12 5.04
Inventories, net		 41 27 25 24 3.16 3.86 3.86 3.38
Prepaid Expenses		 40 36 37 61 3.33 2.31 11 5.69
Other Current Nonoperating Assets		 - - - - 108 133 0.00 0.00
Plant, Property, & Equipment, net		 15 12 11 7.60 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 82 76 73 12 17 16 3.59 8.27
Long-Term Investments		 4.53 5.78 6.91 5.81 - - 3.04 8.03
Other Noncurrent Operating Assets		 75 68 64 4.83 1.12 0.84 0.56 0.25
Other Noncurrent Nonoperating Assets		 2.07 1.66 1.66 1.66 16 15 0.00 0.00
Total Liabilities & Shareholders' Equity		 460 366 293 264 165 178 137 110
Total Liabilities		 576 552 484 466 340 359 120 119
Total Current Liabilities		 209 197 149 191 73 156 36 28
Accounts Payable		 19 4.35 9.94 9.24 7.28 10 5.09 5.09
Accrued Expenses		 171 164 114 151 35 36 26 17
Current Deferred Revenue		 7.33 13 9.55 29 23 27 5.10 5.68
Other Current Liabilities		 12 15 16 1.29 0.00 0.00 0.00 0.00
Other Current Nonoperating Liabilities		 - - - - 8.28 8.46 0.00 0.00
Total Noncurrent Liabilities		 366 355 335 276 267 203 84 91
Long-Term Debt		 72 72 72 73 73 0.00 0.00 0.00
Noncurrent Deferred Revenue		 154 147 131 126 115 122 0.57 4.08
Other Noncurrent Operating Liabilities		 140 136 131 77 78 81 83 87
Other Noncurrent Nonoperating Liabilities		 - - - - 0.19 0.16 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 21 21 21 21 21 21 21 21
Total Equity & Noncontrolling Interests		 -137 -208 -212 -223 -196 -203 -4.00 -31
Total Preferred & Common Equity		 -157 -228 -232 -244 -217 -223 -17 -44
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -157 -228 -232 -244 -217 -223 -17 -44
Common Stock		 1,635 1,653 1,662 1,669 1,672 1,674 1,677 1,679
Retained Earnings		 -1,786 -1,875 -1,890 -1,907 -1,885 -1,892 -1,692 -1,721
Accumulated Other Comprehensive Income / (Loss)		 -6.92 -6.51 -3.81 -5.63 -4.43 -4.79 -2.21 -1.89
Noncontrolling Interest		 20 20 20 20 20 20 13 13

Annual Metrics And Ratios for FibroGen

This table displays calculated financial ratios and metrics derived from FibroGen's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 61,335,151.00 63,160,110.00 82,008,777.00 84,978,056.00 87,250,064.00 91,010,718.00 92,709,943.00 93,957,688.00 98,340,219.00 - 4,045,445.00
DEI Adjusted Shares Outstanding		 2,453,406.00 2,526,404.00 3,280,351.00 3,399,122.00 3,490,003.00 3,640,429.00 3,708,398.00 3,758,308.00 3,933,609.00 - 4,045,445.00
DEI Earnings Per Adjusted Shares Outstanding		 -34.96 -22.98 - -25.42 -22.05 -52.00 -78.21 -78.13 -72.26 - 45.35
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.41% 1.31% 0.00% 0.00% 20.48% -31.28% 33.46% -40.19% -66.74% -36.71% -78.26%
EBITDA Growth		 -53.31% 40.14% 119.25% -1,109.35% 30.18% -193.28% -65.87% -3.26% -10.33% 53.55% 70.66%
EBIT Growth		 -54.93% 35.53% 100.00% 0.00% 14.91% -152.59% -55.43% -1.32% -7.39% 53.95% 70.40%
NOPAT Growth		 -54.93% 35.53% 100.00% 0.00% -3.02% -114.84% -50.37% -4.33% -7.21% 53.39% 69.49%
Net Income Growth		 -44.16% 32.31% 0.00% 0.00% 10.94% -145.93% -53.22% -1.25% 3.21% 83.26% 485.57%
EPS Growth		 55.21% 34.51% 0.00% 0.00% 13.59% -137.08% -48.82% 0.00% 7.01% 83.56% 481.58%
Operating Cash Flow Growth		 -182.85% 138.27% -1,035.75% -14.48% -3.36% 203.68% -200.77% -77.47% -115.87% 56.19% 96.54%
Free Cash Flow Firm Growth		 29.26% 92.03% 2,206.95% -324.13% 15.99% 174.32% -212.22% -63.13% -160.28% 41.76% 7.14%
Invested Capital Growth		 -409.23% -171.91% -94.72% 48.78% 57.63% -928.14% -55.63% -24.36% 23.17% 25.43% 58.00%
Revenue Q/Q Growth		 4.83% 6.44% 0.00% 0.00% 17.25% -34.07% -17.08% 14.50% -69.80% -83.55% -22.40%
EBITDA Q/Q Growth		 0.44% 33.49% 107.86% -1,223.66% 16.95% -1,052.52% -40.65% 21.02% -14.35% -38.25% -17.09%
EBIT Q/Q Growth		 -0.61% 29.34% 100.00% 0.00% 9.75% -4,411.55% -36.11% 20.57% -13.28% -37.73% -15.47%
NOPAT Q/Q Growth		 -0.61% 29.34% 100.00% 0.00% -9.28% -3,429.05% -36.56% 18.67% -9.85% -33.17% -16.14%
Net Income Q/Q Growth		 -0.95% 26.54% 0.00% 0.00% -0.26% -3,558.63% -35.16% 18.78% 3.38% 60.93% -14.93%
EPS Q/Q Growth		 -407.14% 23.14% 0.00% 0.00% -1.14% 0.00% -35.93% 19.28% 4.58% 60.66% -14.93%
Operating Cash Flow Q/Q Growth		 -512.30% 152.07% 20.70% -27.19% -53.96% 86.39% -138.35% 1.65% 9.79% -9.65% 71.77%
Free Cash Flow Firm Q/Q Growth		 0.00% 88.36% 169.25% -334.50% -271.79% 131.15% -154.35% 22.43% -12.31% -68.13% 7.75%
Invested Capital Q/Q Growth		 18.02% 2.02% -71.88% 51.06% 89.90% 0.00% -20.83% -12.47% -10.85% 6.80% -1.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 99.55% 94.97% 94.53% 85.59% 91.53% 47.47% 91.37%
EBITDA Margin		 -38.13% -22.53% 0.00% -37.65% -21.82% -93.11% -115.73% -199.81% -662.90% -486.51% -656.46%
Operating Margin		 -42.93% -27.32% 0.00% -40.71% -34.81% -108.83% -122.62% -213.90% -689.53% -507.80% -712.66%
EBIT Margin		 -42.93% -27.32% 0.00% -40.71% -28.75% -105.68% -123.08% -208.50% -673.31% -489.92% -666.96%
Profit (Net Income) Margin		 -47.44% -31.70% 0.00% -40.58% -30.00% -107.36% -123.25% -208.66% -607.29% -160.63% 2,848.63%
Tax Burden Percent		 100.28% 99.88% 0.00% 100.35% 100.43% 100.30% 99.77% 99.59% 87.94% 31.02% -314.70%
Interest Burden Percent		 110.19% 116.18% 0.00% 99.33% 103.90% 101.29% 100.37% 100.49% 102.57% 105.68% 135.72%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.21% -31.22% 0.00% -16.06% -14.47% -38.76% -86.50% -258.01% 347.30% 27.52% -204.79%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -16.27% -10.65% 0.00% -9.74% -8.49% -22.13% -36.19% -42.41% -60.98% -45.49% -25.71%
Return on Assets (ROA)		 -17.98% -12.35% 0.00% -9.71% -8.86% -22.48% -36.24% -42.44% -55.00% -14.91% 109.81%
Return on Common Equity (ROCE)		 -35.76% -27.99% 0.00% -15.48% -13.95% -37.23% -81.44% -212.74% 478.72% 34.19% -292.21%
Return on Equity Simple (ROE_SIMPLE)		 -48.31% -37.26% 0.00% -16.97% -14.91% -44.84% -138.67% 1,369.21% 139.22% 21.09% 0.00%
Net Operating Profit after Tax (NOPAT)		 -54 -35 0.00 -61 -63 -134 -202 -211 -226 -105 -32
NOPAT Margin		 -30.05% -19.12% 0.00% -28.50% -24.37% -76.18% -85.83% -149.73% -482.67% -355.46% -498.86%
Net Nonoperating Expense Percent (NNEP)		 -13.96% -10.41% 0.00% -4.19% -2.54% -8.99% -14.14% -16.38% -19.27% 48.59% 246.78%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 202.16% 79.75% 188.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.45% 5.03% 5.47% 14.41% 8.47% 52.53% 8.63%
SG&A Expenses to Revenue		 24.53% 25.12% 0.00% 29.96% 52.80% 60.35% 52.66% 88.60% 184.78% 166.54% 430.26%
R&D to Revenue		 118.39% 102.19% 0.00% 110.74% 81.56% 143.45% 164.48% 210.89% 569.35% 323.05% 365.17%
Operating Expenses to Revenue		 142.93% 127.32% 0.00% 140.71% 134.36% 203.80% 217.15% 299.49% 781.07% 555.27% 804.02%
Earnings before Interest and Taxes (EBIT)		 -78 -50 0.00 -87 -74 -186 -290 -293 -315 -145 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -69 -41 7.94 -80 -56 -164 -272 -281 -310 -144 -42
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 10.53 8.67 7.36 7.72 7.25 8.00 6.25 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 10.53 8.67 7.36 7.72 7.25 8.00 6.25 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 10.34 7.38 0.00 18.47 14.58 19.14 5.56 10.70 1.86 1.80 5.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 516.49%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 9.25 6.25 0.00 15.83 12.49 15.49 3.19 7.77 0.00 3.98 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 410.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 160.95 0.00 0.00 0.00 33.47 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 66.50 0.00 0.00 39.83 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.49 0.56 0.18 0.18 0.07 0.06 0.00 0.00 -0.44 -0.40 0.00
Long-Term Debt to Equity		 0.49 0.56 0.18 0.18 0.07 0.06 0.00 0.00 -0.44 -0.40 0.00
Financial Leverage		 -1.03 -1.19 -1.21 -1.14 -1.07 -1.25 -1.86 -4.45 3.70 0.69 0.98
Leverage Ratio		 2.18 2.53 1.89 1.65 1.63 1.72 2.39 6.08 -6.31 -1.85 -1.86
Compound Leverage Factor		 2.40 2.94 0.00 1.64 1.70 1.75 2.40 6.11 -6.48 -1.95 -2.53
Debt to Total Capital		 33.02% 35.73% 15.15% 15.53% 6.56% 5.44% 0.00% 0.00% -79.69% -66.12% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 33.02% 35.73% 15.15% 15.53% 6.56% 5.44% 0.00% 0.00% -79.69% -66.12% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 6.56% 7.07% 2.99% 3.08% 3.36% 4.13% 8.71% -1,349.12% -46.49% -37.96% 771.24%
Common Equity to Total Capital		 60.42% 57.20% 81.87% 81.39% 90.07% 90.43% 91.29% 1,449.12% 226.19% 204.09% -671.24%
Debt to EBITDA		 -1.41 -2.36 12.31 -1.21 -0.67 -0.15 0.00 0.00 -0.23 -0.51 0.00
Net Debt to EBITDA		 3.13 5.50 -81.64 7.24 9.95 4.04 0.00 0.00 0.42 -0.16 0.00
Long-Term Debt to EBITDA		 -1.41 -2.36 12.31 -1.21 -0.67 -0.15 0.00 0.00 -0.23 -0.51 0.00
Debt to NOPAT		 -1.79 -2.78 0.00 -1.60 -0.60 -0.19 0.00 0.00 -0.32 -0.69 0.00
Net Debt to NOPAT		 3.97 6.48 0.00 9.56 8.91 4.94 0.00 0.00 0.58 -0.21 0.00
Long-Term Debt to NOPAT		 -1.79 -2.78 0.00 -1.60 -0.60 -0.19 0.00 0.00 -0.32 -0.69 0.00
Altman Z-Score		 3.06 1.91 6.55 6.30 6.55 3.93 -1.39 -3.02 -8.02 -13.99 -20.22
Noncontrolling Interest Sharing Ratio		 8.81% 10.36% 5.33% 3.58% 3.62% 3.95% 5.85% 17.54% -37.84% -24.27% -42.69%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.99 4.09 8.71 7.75 6.84 4.63 2.10 1.80 1.52 1.47 3.39
Quick Ratio		 2.93 4.05 8.66 7.69 5.47 4.46 1.87 1.60 0.96 0.38 3.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -2.33 49 -110 -92 69 -77 -126 -327 -190 -177
Operating Cash Flow to CapEx		 -940.30% 567.73% -782.97% -971.72% -1,367.59% 2,043.11% -1,585.65% -3,907.18% -12,505.80% 0.00% -12,563.16%
Free Cash Flow to Firm to Interest Expense		 -2.64 -0.22 0.00 -9.99 -32.08 28.55 -71.57 -87.17 -40.36 -23.07 -11.52
Operating Cash Flow to Interest Expense		 -1.68 0.66 0.00 -6.93 -27.37 33.97 -76.49 -101.34 -38.92 -16.73 -0.31
Operating Cash Flow Less CapEx to Interest Expense		 -1.86 0.55 0.00 -7.64 -29.37 32.31 -81.32 -103.94 -39.23 -16.64 -0.31
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.38 0.39 0.00 0.24 0.30 0.21 0.29 0.20 0.09 0.09 0.04
Accounts Receivable Turnover		 12.53 14.17 0.00 5.90 5.57 5.01 7.94 8.35 4.37 10.58 18.48
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.76 0.54 0.57 0.14 1.53 0.16
Fixed Asset Turnover		 1.38 1.45 0.00 1.66 3.02 4.62 7.60 5.76 3.69 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.15 0.57 0.51 0.71 0.17 1.49 0.13
Days Sales Outstanding (DSO)		 29.12 25.76 0.00 61.82 65.54 72.80 45.98 43.70 83.52 34.51 19.75
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 481.86 674.15 642.99 2,653.62 238.41 2,264.18
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 2,422.78 635.37 721.52 511.64 2,143.57 244.44 2,891.44
Cash Conversion Cycle (CCC)		 29.12 25.76 0.00 61.82 -2,357.24 -80.70 -1.39 175.05 593.57 28.49 -607.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -19 -52 -101 -52 -22 -225 -350 -435 -334 -249 -105
Invested Capital Turnover		 -28.10 -5.18 0.00 -2.80 -6.99 -1.43 -0.82 -0.36 -0.12 -0.10 -0.04
Increase / (Decrease) in Invested Capital		 -25 -33 -49 49 30 -203 -125 -85 101 85 145
Enterprise Value (EV)		 1,672 1,144 3,258 3,372 3,204 2,731 750 1,094 -2.39 118 -39
Market Capitalization		 1,869 1,352 3,887 3,933 3,742 3,376 1,307 1,505 87 53 36
Book Value per Share		 $2.89 $2.47 $6.44 $5.99 $5.92 $4.64 $2.26 ($0.23) ($2.08) ($2.24) ($7.43)
Tangible Book Value per Share		 $2.89 $2.47 $6.44 $5.99 $5.92 $4.64 $2.26 ($0.23) ($2.08) ($2.24) ($7.43)
Total Capital		 294 272 646 626 573 467 229 -1.48 -90 -111 4.48
Total Debt		 97 97 98 97 38 25 0.00 0.00 72 73 0.00
Total Long-Term Debt		 97 97 98 97 38 25 0.00 0.00 72 73 0.00
Net Debt		 -216 -227 -648 -580 -557 -664 -577 -431 -132 23 -109
Capital Expenditures (CapEx)		 1.98 1.25 8.50 7.84 5.76 3.99 5.19 3.74 2.52 -0.78 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -48 -52 -73 -20 66 -95 -157 -203 -90 13 -19
Debt-free Net Working Capital (DFNWC)		 133 201 663 601 600 592 249 219 114 63 70
Net Working Capital (NWC)		 133 201 663 601 600 592 249 219 114 63 70
Net Nonoperating Expense (NNE)		 31 23 0.00 26 14 55 88 83 58 -58 -216
Net Nonoperating Obligations (NNO)		 -216 -227 -648 -580 -557 -666 -579 -433 -172 -66 -109
Total Depreciation and Amortization (D&A)		 8.68 8.77 7.94 6.52 18 22 17 12 4.87 1.01 0.68
Debt-free, Cash-free Net Working Capital to Revenue		 -26.43% -28.27% 0.00% -9.59% 25.72% -53.66% -66.56% -144.06% -191.36% 42.95% -297.31%
Debt-free Net Working Capital to Revenue		 73.76% 109.94% 0.00% 282.21% 233.75% 335.71% 105.63% 155.80% 243.34% 213.37% 1,084.33%
Net Working Capital to Revenue		 73.76% 109.94% 0.00% 282.21% 233.75% 335.71% 105.63% 155.80% 243.34% 213.37% 1,084.33%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.42) ($0.98) ($1.73) ($1.03) $0.00 ($2.11) $0.00 ($3.14) ($2.92) ($0.48) $45.37
Adjusted Weighted Average Basic Shares Outstanding		 62.07M 63.89M 82.67M 85.56M 88.00M 91.56M 0.00 93.58M 97.30M 100.04M 4.04M
Adjusted Diluted Earnings per Share		 ($1.42) ($0.98) ($1.73) ($1.03) $0.00 ($2.11) $0.00 ($3.14) ($2.92) ($0.48) $45.37
Adjusted Weighted Average Diluted Shares Outstanding		 62.07M 63.89M 82.67M 85.56M 88.00M 91.56M 0.00 93.58M 97.30M 100.04M 4.04M
Adjusted Basic & Diluted Earnings per Share		 ($1.42) ($0.98) ($1.73) ($1.03) $0.00 ($2.11) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.34M 62.74M 72.99M 84.06M 88.00M 89.85M 0.00 94.18M 98.77M 100.92M 4.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -54 -35 0.00 -61 -63 -134 -202 -211 -217 -92 -32
Normalized NOPAT Margin		 -30.05% -19.12% 0.00% -28.50% -24.37% -76.18% -85.83% -149.73% -463.82% -309.49% -492.85%
Pre Tax Income Margin		 -47.30% -31.74% 0.00% -40.44% -29.87% -107.04% -123.53% -209.52% -690.60% -517.76% -905.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.04 -4.67 0.00 -7.89 -25.65 -77.57 -269.40 -203.77 -38.93 -17.60 -2.80
NOPAT to Interest Expense		 -4.93 -3.27 0.00 -5.52 -21.74 -55.92 -187.88 -146.33 -27.91 -12.77 -2.09
EBIT Less CapEx to Interest Expense		 -7.21 -4.78 0.00 -8.60 -27.65 -79.23 -274.23 -206.36 -39.24 -17.50 -2.80
NOPAT Less CapEx to Interest Expense		 -5.10 -3.38 0.00 -6.23 -23.74 -57.58 -192.70 -148.93 -28.22 -12.67 -2.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.92%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.92%

Quarterly Metrics And Ratios for FibroGen

This table displays calculated financial ratios and metrics derived from FibroGen's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 98,210,168.00 98,340,219.00 98,340,219.00 99,475,398.00 100,400,786.00 - 100,916,956.00 101,043,970.00 4,043,899.00 4,045,445.00 4,046,827.00
DEI Adjusted Shares Outstanding		 3,928,407.00 3,933,609.00 3,933,609.00 3,979,016.00 4,016,031.00 - 4,036,678.00 4,041,759.00 4,043,899.00 4,045,445.00 4,046,827.00
DEI Earnings Per Adjusted Shares Outstanding		 -16.19 -14.30 -8.37 -3.91 -4.25 - 1.15 -1.88 49.61 -3.52 -3.76
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 155.06% -314.78% -29.86% -97.75% -99.69% -66.99% -89.20% 35.07% 774.80% -59.28% 36.47%
EBITDA Growth		 35.30% -69.42% 34.84% 46.17% 22.45% 4.13% 70.10% 74.41% 90.58% -101.28% 9.17%
EBIT Growth		 36.81% -63.08% 37.45% 46.71% 21.91% 4.23% 69.10% 74.15% 90.31% -89.28% 12.42%
NOPAT Growth		 32.22% -43.76% 35.36% 47.29% 24.87% 3.62% 69.66% 74.03% 88.65% -89.40% 7.39%
Net Income Growth		 30.59% 15.03% 57.07% 82.27% 73.14% 131.98% 114.09% 51.09% 1,274.41% -179.08% -427.61%
EPS Growth		 33.67% 20.00% 59.26% 82.27% 73.14% 132.14% 114.09% 51.67% 1,267.29% -178.40% -426.96%
Operating Cash Flow Growth		 -62.95% 65.11% 41.64% 63.94% 90.09% -66.29% 104.59% 131.81% 77.95% 39.84% -610.74%
Free Cash Flow Firm Growth		 -509.01% -530.30% -1,151.30% -2.51% 47.97% 10.89% 54.06% 93.86% -148.45% -71.19% -164.19%
Invested Capital Growth		 22.04% 23.17% 23.88% 19.72% 11.31% 25.43% 16.21% -0.90% 61.28% 58.00% 58.26%
Revenue Q/Q Growth		 -9.44% -283.91% 134.36% -96.07% -87.68% -366.02% -12.66% -50.79% -20.18% 18.68% 192.72%
EBITDA Q/Q Growth		 30.02% -62.02% 50.09% 4.86% -0.81% -644.52% -132.74% 18.59% 62.88% -186.14% -5.03%
EBIT Q/Q Growth		 30.69% -61.34% 50.84% 3.07% -1.56% -604.77% -125.09% 18.89% 61.92% -172.30% -4.15%
NOPAT Q/Q Growth		 27.90% -49.81% 48.28% 5.64% -2.77% -446.29% -109.14% 19.22% 55.10% -149.71% -2.26%
Net Income Q/Q Growth		 27.45% 11.61% 41.43% 52.80% -9.91% 205.26% -74.20% -263.89% 2,738.91% -107.09% -6.88%
EPS Q/Q Growth		 27.78% 13.85% 41.07% 52.80% -9.91% 205.88% -74.20% -3,860.00% 2,738.83% -107.10% -6.82%
Operating Cash Flow Q/Q Growth		 23.54% 78.33% -223.61% 32.75% 78.99% -263.73% 108.92% 366.42% -114.56% -892.31% 24.23%
Free Cash Flow Firm Q/Q Growth		 -35.50% -29.05% 23.37% 23.50% 31.22% -225.33% 34.52% 89.78% -2,684.25% 8.14% -1.05%
Invested Capital Q/Q Growth		 9.41% -10.85% 10.53% 10.64% -0.08% 6.80% -0.52% -7.62% 61.60% -1.10% 0.11%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.43% 0.00% 15.85% 85.97% 160.98% 0.00% 90.80% 93.69% 105.39% 78.31% -9.84%
EBITDA Margin		 -146.13% 0.00% -186.96% -4,520.44% -36,975.61% 0.00% -517.74% -856.45% -398.33% -960.38% -344.60%
Operating Margin		 -158.18% 0.00% -193.90% -4,650.10% -38,773.98% 0.00% -544.72% -894.07% -502.88% -1,058.10% -369.66%
EBIT Margin		 -147.47% 0.00% -185.09% -4,559.92% -37,577.24% 0.00% -529.65% -872.85% -416.36% -955.29% -339.89%
Profit (Net Income) Margin		 -158.51% 0.00% -129.84% -1,557.52% -13,889.43% 0.00% 169.37% -564.02% 18,646.47% -1,113.55% -406.58%
Tax Burden Percent		 99.08% 60.39% 67.16% 32.81% 35.38% -21.17% -27.67% 55.19% -1,526.21% 97.34% 100.44%
Interest Burden Percent		 108.49% 97.52% 104.46% 104.10% 104.48% 92.86% 115.56% 117.07% 293.44% 119.76% 119.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 853.56% 347.30% 223.64% 134.29% 76.86% 27.52% 5.54% 1.11% -234.13% -204.79% -177.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -42.75% 0.00% -14.74% 0.00% 0.00% 0.00% -13.95% -27.21% -17.22% -36.83% -18.40%
Return on Assets (ROA)		 -45.95% 0.00% -10.34% 0.00% 0.00% 0.00% 4.46% -17.58% 770.97% -42.93% -22.01%
Return on Common Equity (ROCE)		 1,620.50% 478.72% 288.05% 179.26% 97.22% 34.19% 6.83% 1.36% -331.34% -292.21% -251.38%
Return on Equity Simple (ROE_SIMPLE)		 187.17% 0.00% 105.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 -67 -34 -32 -33 -64 -10 -8.44 -3.79 -9.46 -9.67
NOPAT Margin		 -110.72% 0.00% -135.73% -3,255.07% -27,141.79% 0.00% -381.31% -625.85% -352.02% -740.67% -258.76%
Net Nonoperating Expense Percent (NNEP)		 -6.19% 3.41% 0.63% 9.70% 12.94% 69.15% 16.01% 1.01% 218.99% -5.45% -6.47%
Return On Investment Capital (ROIC_SIMPLE)		 - 59.57% 25.42% 23.31% 22.20% 48.60% 8.49% 6.55% 94.81% 55.62% 31.44%
Cost of Revenue to Revenue		 10.57% 0.00% 84.15% 14.03% -60.98% 0.00% 9.20% 6.31% -5.39% 21.69% 109.84%
SG&A Expenses to Revenue		 63.72% 0.00% 65.90% 1,493.59% 7,611.38% 0.00% 295.95% 523.52% 492.10% 567.82% 156.82%
R&D to Revenue		 152.47% 0.00% 143.86% 3,242.49% 16,239.02% 0.00% 334.98% 435.09% 112.36% 569.15% 202.41%
Operating Expenses to Revenue		 247.60% 0.00% 209.76% 4,736.07% 38,934.96% 0.00% 635.52% 987.76% 608.27% 1,136.41% 359.82%
Earnings before Interest and Taxes (EBIT)		 -59 -95 -47 -46 -46 -91 -15 -12 -4.48 -12 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -59 -95 -47 -45 -45 -91 -14 -12 -4.29 -12 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.55 1.86 6.42 0.00 0.00 1.80 4.47 2.92 5.97 5.52 3.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.19 0.17
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 435.33% 516.49% 596.32%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 4.50 0.00 0.00 3.98 16.16 15.49 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.62 -0.44 -0.39 -0.38 -0.36 -0.40 -0.42 -0.41 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.62 -0.44 -0.39 -0.38 -0.36 -0.40 -0.42 0.00 0.00 0.00 0.00
Financial Leverage		 8.98 3.70 2.22 1.39 0.80 0.69 0.52 0.45 1.01 0.98 0.93
Leverage Ratio		 -15.51 -6.31 -4.21 -3.22 -2.29 -1.85 -1.47 -1.27 -2.18 -1.86 -1.49
Compound Leverage Factor		 -16.83 -6.16 -4.39 -3.36 -2.39 -1.71 -1.70 -1.49 -6.39 -2.23 -1.78
Debt to Total Capital		 -164.61% -79.69% -63.38% -61.48% -56.45% -66.12% -72.33% -68.72% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -68.72% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -164.61% -79.69% -63.38% -61.48% -56.45% -66.12% -72.33% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -96.40% -46.49% -36.83% -35.60% -32.55% -37.96% -41.34% -39.11% 197.39% 771.24% -371.51%
Common Equity to Total Capital		 361.01% 226.19% 200.21% 197.07% 189.00% 204.09% 213.67% 207.83% -97.39% -671.24% 471.51%
Debt to EBITDA		 -0.26 -0.23 -0.25 -0.29 -0.31 -0.51 -0.66 -0.95 0.00 0.00 0.00
Net Debt to EBITDA		 0.68 0.42 0.39 0.31 0.27 -0.16 -0.36 -0.65 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.26 -0.23 -0.25 -0.29 -0.31 -0.51 -0.66 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.35 -0.32 -0.35 -0.41 -0.44 -0.69 -0.90 -1.29 0.00 0.00 0.00
Net Debt to NOPAT		 0.90 0.58 0.54 0.42 0.38 -0.21 -0.49 -0.88 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.35 -0.32 -0.35 -0.41 -0.44 -0.69 -0.90 0.00 0.00 0.00 0.00
Altman Z-Score		 -5.03 -6.31 -6.98 -9.20 -10.56 -13.17 -15.62 -14.98 -16.23 -19.37 -21.36
Noncontrolling Interest Sharing Ratio		 -89.85% -37.84% -28.80% -33.48% -26.49% -24.27% -23.25% -22.60% -41.52% -42.69% -41.52%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.74 1.52 1.41 1.41 1.28 1.47 2.02 1.04 3.71 3.39 3.61
Quick Ratio		 1.35 0.96 1.09 0.99 0.84 0.38 0.46 0.15 3.28 3.05 3.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -130 -167 -128 -98 -67 -149 -59 -6.02 -168 -154 -156
Operating Cash Flow to CapEx		 -12,359.36% -7,299.20% -204,441.38% -362,445.45% 0.00% 0.00% 16,993.75% 97,553.85% -20,522.22% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -25.82 0.00 -61.30 -52.52 -32.61 0.00 -26.10 -3.00 -19.35 -63.90 -64.12
Operating Cash Flow to Interest Expense		 -16.83 0.00 -28.34 -21.34 -4.05 0.00 1.20 6.31 -0.21 -7.61 -5.72
Operating Cash Flow Less CapEx to Interest Expense		 -16.97 0.00 -28.35 -21.35 -3.68 0.00 1.20 6.31 -0.21 -7.61 -5.72
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.29 0.09 0.08 0.00 0.00 0.09 0.03 0.03 0.04 0.04 0.05
Accounts Receivable Turnover		 6.59 4.37 1.32 0.00 0.00 10.58 0.38 2.24 0.57 18.48 2.87
Inventory Turnover		 0.46 0.14 0.63 0.49 0.37 1.53 0.00 0.00 0.00 0.16 1.35
Fixed Asset Turnover		 8.42 3.69 2.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.95 0.17 0.58 1.43 0.84 1.49 0.00 0.00 0.00 0.13 0.71
Days Sales Outstanding (DSO)		 55.37 83.52 277.44 0.00 0.00 34.51 971.19 162.67 641.05 19.75 127.25
Days Inventory Outstanding (DIO)		 801.32 2,653.62 583.88 747.88 988.89 238.41 0.00 0.00 0.00 2,264.18 270.60
Days Payable Outstanding (DPO)		 382.97 2,143.57 632.78 255.45 435.41 244.44 0.00 0.00 0.00 2,891.44 512.16
Cash Conversion Cycle (CCC)		 473.72 593.57 228.55 0.00 0.00 28.49 971.19 162.67 641.05 -607.51 -114.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -301 -334 -299 -267 -267 -249 -251 -270 -104 -105 -105
Invested Capital Turnover		 -0.45 -0.12 -0.10 0.00 0.00 -0.10 -0.03 -0.03 -0.04 -0.04 -0.04
Increase / (Decrease) in Invested Capital		 85 101 94 66 34 85 48 -2.42 164 145 146
Enterprise Value (EV)		 -57 -2.39 162 56 18 118 113 114 -37 -39 -33
Market Capitalization		 85 87 231 89 40 53 31 21 50 36 27
Book Value per Share		 ($1.60) ($2.08) ($2.30) ($2.34) ($2.43) ($2.24) ($2.15) ($2.21) ($4.21) ($7.43) ($10.82)
Tangible Book Value per Share		 ($1.60) ($2.08) ($2.30) ($2.34) ($2.43) ($2.24) ($2.15) ($2.21) ($4.21) ($7.43) ($10.82)
Total Capital		 -44 -90 -114 -118 -129 -111 -102 -107 17 4.48 -9.29
Total Debt		 72 72 72 72 73 73 73 74 0.00 0.00 0.00
Total Long-Term Debt		 72 72 72 72 73 73 73 0.00 0.00 0.00 0.00
Net Debt		 -184 -132 -111 -75 -64 23 40 50 -121 -109 -95
Capital Expenditures (CapEx)		 0.68 0.25 0.03 0.01 -0.76 -0.07 0.02 0.01 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -97 -90 -96 -80 -77 13 42 57 -21 -19 -14
Debt-free Net Working Capital (DFNWC)		 155 114 81 61 54 63 75 80 97 70 73
Net Working Capital (NWC)		 155 114 81 61 54 63 75 6.43 97 70 73
Net Nonoperating Expense (NNE)		 19 -10 -1.49 -17 -16 -82 -15 -0.83 -204 4.76 5.53
Net Nonoperating Obligations (NNO)		 -186 -172 -113 -77 -66 -66 -76 -89 -121 -109 -95
Total Depreciation and Amortization (D&A)		 0.54 0.47 -0.47 0.39 0.74 0.35 0.33 0.22 0.19 -0.07 -0.18
Debt-free, Cash-free Net Working Capital to Revenue		 -62.36% -191.36% -267.08% 0.00% 0.00% 42.95% 593.62% 773.11% -247.32% -297.31% -188.14%
Debt-free Net Working Capital to Revenue		 99.81% 243.34% 226.17% 0.00% 0.00% 213.37% 1,074.03% 1,091.21% 1,174.24% 1,084.33% 984.55%
Net Working Capital to Revenue		 99.81% 243.34% 226.17% 0.00% 0.00% 213.37% 1,074.03% 87.49% 1,174.24% 1,084.33% 984.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.65) ($0.56) ($0.33) ($4.00) ($4.25) $0.18 $1.25 ($1.88) $49.61 ($3.52) ($3.76)
Adjusted Weighted Average Basic Shares Outstanding		 98.25M 97.30M 98.98M 3.99M 4.02M 100.04M 4.04M 4.04M 4.04M 4.04M 4.05M
Adjusted Diluted Earnings per Share		 ($0.65) ($0.56) ($0.33) ($4.00) ($4.25) $0.18 $1.25 ($1.88) $49.61 ($3.52) ($3.76)
Adjusted Weighted Average Diluted Shares Outstanding		 98.25M 97.30M 98.98M 3.99M 4.02M 100.04M 4.04M 4.04M 4.04M 4.04M 4.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.52) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.34M 98.77M 99.48M 4.02M 4.03M 100.92M 4.04M 4.04M 4.05M 4.05M 4.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -67 -34 -32 -20 -64 -10 -8.16 -3.76 -9.46 -9.66
Normalized NOPAT Margin		 -88.74% 0.00% -135.73% -3,255.07% -16,582.60% 0.00% -378.09% -605.44% -349.35% -741.06% -258.35%
Pre Tax Income Margin		 -159.98% 0.00% -193.34% -4,747.09% -39,259.35% 0.00% -612.05% -1,021.88% -1,221.75% -1,144.01% -404.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -11.79 0.00 -22.44 -24.36 -22.34 0.00 -6.43 -5.86 -0.52 -5.06 -5.23
NOPAT to Interest Expense		 -8.85 0.00 -16.46 -17.39 -16.14 0.00 -4.63 -4.20 -0.44 -3.92 -3.99
EBIT Less CapEx to Interest Expense		 -11.92 0.00 -22.46 -24.37 -21.97 0.00 -6.43 -5.86 -0.52 -5.06 -5.23
NOPAT Less CapEx to Interest Expense		 -8.98 0.00 -16.47 -17.40 -15.77 0.00 -4.63 -4.21 -0.44 -3.92 -3.99
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.92% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.92% 0.00%

Financials Breakdown Chart

Key Financial Trends

Kyntra Bio (NASDAQ: KYNB) has shown a major balance-sheet improvement in the most recent quarter, but profitability and operating cash flow remain under pressure. The company ended Q1 2026 with a much stronger cash position than it had earlier in 2025, yet it still posted a sizable quarterly loss and negative operating cash flow. For retail investors, the key takeaway is that liquidity improved, but the underlying business is still not generating consistent profits.

  • Cash and investments improved sharply in Q1 2026. KYNB reported $36.9 million in cash and equivalents, $50.2 million in short-term investments, and $8.0 million in long-term investments, giving it a solid liquidity buffer near term.
  • The company reduced leverage. Long-term debt was $0 in Q1 2026, compared with meaningful debt on the balance sheet in earlier periods, which lowers financial risk.
  • Operating cash burn improved from late 2025. Net cash used in operating activities was -$13.9 million in Q1 2026, better than -$18.3 million in Q4 2025.
  • Revenue grew year over year in the latest quarter. Q1 2026 revenue was $3.7 million, up from $2.7 million in Q1 2025 and above Q4 2025’s $1.3 million.
  • Gross profit was still negative, but less severe than in some prior quarters. Q1 2026 gross loss was only -$0.4 million, indicating cost of revenue was closer to matching sales than in earlier periods.
  • Short-term liquidity appears manageable for now. Current assets of $101.4 million exceeded current liabilities of $28.1 million in Q1 2026.
  • Quarterly performance was still loss-making. Q1 2026 net loss attributable to common shareholders was $15.2 million, or -$3.76 per share.
  • R&D spending remains substantial. Research and development expense was $7.6 million in Q1 2026, showing the company is still investing heavily in its pipeline.
  • There is still a large redeemable noncontrolling interest on the balance sheet. That line item was $21.5 million in Q1 2026 and can complicate equity analysis for investors.
  • Operating losses remain significant. The company reported operating income of -$13.8 million in Q1 2026, reflecting a business that is still far from break-even.
  • Cash flow from operations has been negative in most recent quarters. Despite improvement, Q1 2026 and Q4 2025 both showed negative operating cash flow.
  • Retained earnings remain deeply negative. Retained earnings stood at -$1.72 billion in Q1 2026, highlighting the long history of losses.
  • Equity remains negative. Total common equity was -$43.8 million in Q1 2026, which is a caution sign for investors.
  • The business has been highly volatile over the last four years. Revenue, earnings, and cash flow have swung sharply quarter to quarter, including periods with very large one-time items and discontinued operations gains/losses.

Bottom line: KYNB’s latest quarter shows better liquidity and less debt, which are encouraging signs. However, the company is still burning cash and posting losses, so the investment case likely depends on whether it can turn revenue growth into sustained operating improvement. Investors should watch future quarters for margin recovery, lower operating losses, and continued balance-sheet stability.

07/21/26 08:02 AM ETAI Generated. May Contain Errors.

FibroGen Financials - Frequently Asked Questions

According to the most recent income statement we have on file, FibroGen's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, FibroGen's net income changed from -$85.78 million in 2015 to $183.45 million in 2025, a change of -313.9%.

FibroGen's total operating income in 2025 was -$45.90 million, based on the following breakdown:
  • Total Gross Profit: $5.88 million
  • Total Operating Expenses: $51.78 million

Over the last 10 years, FibroGen's total revenue changed from $180.83 million in 2015 to $6.44 million in 2025, a change of -96.4%.

FibroGen's total liabilities were at $115.12 million at the end of 2025, a 71.1% decrease from 2024, and a 57.9% decrease since 2015.

In the past 10 years, FibroGen's cash and equivalents has ranged from $47.87 million in 2025 to $678.39 million in 2020, and is currently $47.87 million as of their latest financial filing in 2025.

Over the last 10 years, FibroGen's book value per share changed from 2.89 in 2015 to -7.43 in 2025, a change of -356.5%.


Related Companies

Financial statements for NASDAQ:FGEN last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel